# TRITON3 (NCT02975934)

> A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02975934
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: pharmaand GmbH
- Conditions: Metastatic Castration Resistant Prostate Cancer
- Interventions: Rucaparib; Abiraterone acetate or Enzalutamide or Docetaxel
- Enrollment: 405
- Primary outcome: Radiographic Progression-free Survival (rPFS) by IRR in Participants With a BRCA Alteration
- Primary outcome: Radiographic Progression-free Survival (rPFS) by IRR in Participants With a BRCA or ATM Alteration Combined

## Commentary we found

- Podcasts: 51
- X threads: 49
- YouTube: 14

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=triton3-nct02975934

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02975934", "email": "<work email>"}; the inbox owner confirms by the emailed link.